Crofelemer · Mytesi

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: HIV-Associated Diarrhea

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Short Bowel Syndrome · Phase 2

Company guidance: regulatory filing expected mid-2027 (Jaguar Health, 16 Nov 2026). “crofelemer powder for oral solution is expected to continue to provide clinical milestones, including a planned New Drug Application (NDA) filing for crofelemer for MVID in mid-2027” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (4)
HIV-Associated Diarrhea
NCT01374490 · Bausch Health Americas, Inc.
2011-06-07 – 2012-10-31 · HIV Enteropathy, Diarrhea With HIV
What this study did
Other / comorbidity
NCT04538625 · Napo Pharmaceuticals, Inc.
2020-10-07 – 2023-10-30 · Cancer Therapy-Related Diarrhea, Chemotherapy-related Diarrhea, Adult Solid Tumor, Prophylaxis of Diarrhea, Symptomatic Relief of Diarrhea, Targeted Therapy-related Diarrhea
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT06721871 · Napo Pharmaceuticals, Inc.
2025-05-01 – 2026-12 · Microvillus Inclusion Disease, Congenital Disorders, Rare Diseases
What this study did
Phase 2 (5)
Short Bowel Syndrome
Other / comorbidity
NCT03094052 · University of California, San Francisco
2018-10-09 – 2022-10-31 · HER2-positive Breast Cancer, Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
What this study did
NCT02910219 · Sandra Swain
2017-01-31 – 2020-11-23 · Breast Cancer
What this study did
NCT00461526 · Bausch Health Americas, Inc.
2006-10 – 2007-12 · Irritable Bowel Syndrome
What this study did
NCT00101725 · Bausch Health Americas, Inc.
2004-12 – 2005-11 · Irritable Bowel Syndrome, Colonic Diseases, Diarrhea, Gastrointestinal Disease
What this study did
Phase 1 (1)
Short Bowel Syndrome
NCT06326645 · Jessica Sosio
2025-03-03 – 2026-10-01 · Short Bowel Syndrome
What this study did
Phase 4 (3)
Other / comorbidity
NCT03898856 · The University of Texas Health Science Center, Houston
2019-04-01 – 2025-01-30 · Chronic Diarrhea of Unknown Origin
What this study did
NCT04486326 · Beth Israel Deaconess Medical Center
2020-08-20 – 2022-09-23 · Diarrhea
What this study did
NCT04192487 · Napo Pharmaceuticals, Inc.
2019-10-22 – 2021-08-31 · Acquired Immunodeficiency Syndrome, Healthy Volunteers, HIV/AIDS, HIV Diarrhea, Human Immunodeficiency Virus
What this study did
Early phase / not applicable (2)

Competitive landscape

This drug's own stage for Short Bowel Syndrome: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Crofelemer (Mytesi): this drugPhase 2Small moleculeChloride channel (intestinal epithelium)not yet gradedNo reviewed efficacy summary in this indication
Teduglutide (Gattex)ApprovedPeptideGLP-2 receptorPartial signal
NCT02682381: Number of Participants Who Achieved at Least a 20 Percent (%) Reduction in Weight-Normalized Average Daily Parenteral Nutrition Intravenous (PN/IV) Volume at Week 24 (Baseline through Week 24): 0.025 mg/kg/Day Teduglutide — Participant Diary: 13 Participants; Investigator Prescribed: 13 Participants | 0.05 mg/kg/Day Teduglutide — Participant Diary: 18 Participants; Investigator Prescribed: 18 Participants | Standard of Care — Participant Diary: 1 Participants; Investigator Prescribed: 2 Participants
NCT00798967: Responder (Weeks 20 and 24): Teduglutide 27 subjects | Placebo 13 subjects
ApraglutidePhase 3PeptideGLP-2 receptornot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Mytesi (Crofelemer) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2/3Microvillus Inclusion Disease, Congenital Disorders, Rare DiseasesActive not recruiting
Est. primary completion 2026-12 · NCT06721871 · CT.gov ↗
What to watch
2027 (1)
March 2027 (1)
Phase 2Short Bowel SyndromeRecruiting
Est. primary completion 2027-03 · NCT06904872 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 July 2024Topline resultPhase 3 OnTarget: primary endpoint not met across all tumor types